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Abstract: Background and Objective: Obesity is an important contributor to the risk of both asthma 
and Type 2 Diabetes (T2DM). However, it has been suggested that T2DM and asthma are also inde-
pendently associated. The aim of this systematic review was to synthesize the evidence for an inde-
pendent relationship between T2DM and asthma.  
Methods: MEDLINE and EMBASE were searched for studies reporting the relationship between 
asthma and T2DM in adults. Given a potential bidirectional relationship, articles relating to T2DM as 
a risk factor for asthma, and asthma as a risk factor for T2DM were examined separately. 
Results: Eight studies were identified for inclusion in the review (n=2,934,399 participants). Four studies 
examined incident diabetes in those with asthma. The pooled (random effects model) adjusted hazard 
ratio for incident T2DM in asthma was 1.37 (95%CI 1.12-1.69; p <0.001) after controlling for BMI. 
Four studies reported prevalence or incidence rates of asthma in people with T2DM; higher rates of 
asthma in those with T2DM were reported in all four studies. Meta-analysis of results was not possi-
ble due to methodological heterogeneity.  
The quality of included studies was good, but due to small numbers, publication bias cannot be ex-
cluded. 
Conclusion: The published literature suggests a bidirectional independent relationship between 
T2DM and asthma, although we cannot exclude publication bias. 
Keywords: Type 2 diabetes, asthma, obesity, BMI, incidence. 
1. INTRODUCTION 
For decades, asthma has been viewed as a purely atopic 
disease. This assertion; although well documented, is now 
thought to be an oversimplification. More recently, asthma 
has tentatively been considered as a syndrome, with differ-
ences in pathophysiology, onset, co-morbidities and treat-
ment response between patient groups [1, 2]. Of the emerg-
ing co-morbidities in asthma, obesity is one of the most fre-
quently reported. The odds ratio of asthma in obese indi-
viduals compared with those of a normal BMI has been re-
ported as 2.92 (95% CI 1.39-6.14) in males and 2.67 (95% 
CI 1.66-4.29) in females (3] and increasing adiposity is 
thought to be associated with a dose-dependent increase in 
the odds of incident asthma [4]. Obesity has also been shown 
to influence asthma severity; obese patients with asthma ex-
perience more frequent exacerbations, a poorer response to 
treatment and a higher rate of hospitalisation compared to 
normal-weight asthma patients [5]. 
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A number of large-scale epidemiological studies have 
provided evidence in favor of a relationship between asthma 
and Type 2 Diabetes (T2DM), another component of the 
metabolic syndrome, however, this has not been uniformly 
replicated [6]. Obesity is a common risk factor for both con-
ditions; the relative risk of T2DM in obese compared with 
normal weight adults as 4.03 (95% CI 2.66-6.09) [7]. Fur-
thermore, whilst some studies have looked at asthma-
induced chronic inflammation as a risk factor for incident 
T2DM [8], other works have focused upon T2DM and the 
associated hyperglycaemia-induced biochemical alterations 
as the driving force for the development of asthma [9,10], 
raising the possibility of a bidirectional relationship.  
To clarify the association between asthma and T2DM, we 
conducted a systematic review of the available literature 
linking the two conditions. In adults with asthma, compared 
to those without asthma, is there a higher rate of T2DM? 
Furthermore, given a potential bidirectional relationship, in 
adults with T2DM, compared to those without T2DM, is 
there a higher rate of asthma? To our knowledge, this is the 
first systematic review with the primary objective of 
analysing the relationship between these conditions. 
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2. MATERIALS AND METHODS 
2.1. Ethics and Registration 
In accordance with the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) [11] and 
MOOSE (Meta-analyses of Observational Studies in Epide-
miology) [12] guidelines, we registered the objectives, inclu-
sion criteria, search strategies and methods with the Interna-
tional Prospective Register of Systematic Reviews; PROS-
PERO [13], in May 2017, and published it in the open litera-
ture [14]. We ensured all included studies had obtained ethi-
cal approval. 
2.2. Search Strategy 
We searched MEDLINE (Ovid) and EMBASE (Ovid) 
databases for relevant articles published from 2002 up to 10th 
May 2017. Included studies were limited to those published 
in the last 15 years. A free-text keyword search was per-
formed using the terms “asthma” and “diabetes”, and was 
restricted to the English language only. We combined 
searches using the AND Boolean logic operator. We sup-
plemented the database search with a manual search of the 
reference lists of included studies and previous reviews.  
2.3. Study Selection 
We included studies which were relevant to the scope of 
the review; because they examined the relationship, direc-
tionality or comorbidities of T2DM and asthma. We in-
cluded all studies which did or did not demonstrate an asso-
ciation between asthma and diabetes. Studies were excluded 
if they related solely to children (age < 18 years), type 1 dia-
betes (T1DM, but mixed samples of T2DM and T1DM were 
included), or gestational diabetes. Studies examining the 
effect of medications on the development of T2DM or 
asthma, those which reported biological markers as the pri-
mary outcomes; and reviews, editorials and comments were 
also excluded. We did not place restrictions on how the in-
dex conditions were defined, but considered this in the ap-
praisal process.  
Titles and abstracts of records identified in the database 
search were reviewed independently by two reviewers. Any 
discrepancies were discussed between the reviewers and 
were included for full-text searching. Full-texts were then 
retrieved and also independently reviewed against the inclu-
sion criteria by the two reviewers. Any discrepancies were 
resolved by discussion with a third independent reviewer. 
Where the full text was not available, we contacted the cor-
responding authors. 
2.4. Study Appraisal and Data Analysis 
We grouped the included studies according to the direc-
tion in which they examined the asthma-T2DM relationship. 
We examined each study for study design, population, data 
collection, adjustment for confounding variables and results. 
Study quality was assessed using the Newcastle-Ottawa 
Scale for cross-sectional and cohort studies [15]. Risk of bias 
was considered and commented upon in the narrative synthe-
sis and appendix.  
Based upon the number and methodological similarities 
between the available studies, we determined whether pooled 
estimate effects by meta-analysis could be calculated, and 
presented this in addition to the narrative synthesis of the 
literature. We assessed each paper for consideration of Body 
Mass Index (BMI), a potential confounding factor, and used 
the effect size (hazard ratio or relative risk) calculated after 
adjustment for BMI as the study outcome where available. 
Other factors controlled were considered in the narrative 
synthesis and included smoking status and medications.  
Where three or more studies used comparable methods, 
we performed a meta-analysis using the software package R 
(version 3.3.2) and the R meta-analysis package ‘Meta’ [16]. 
We used the DerSimonian and Laird method [17], a non-
iterative process for estimation of effect size distribution. 
The assigned weight of each study in the analysis was based 
on its inverse variance [18]. Where odds ratios were not 
available these were estimated from reported event rates us-
ing the approach described by Tierney et al. [19]. We re-
ported both fixed and random effects pooled estimates with 
95% confidence intervals (95% CI). Heterogeneity between 
studies was quantified using the I² statistic (with 95% CI) 
[20] and Tau² (also estimated using the DerSimonian and 
Laird method) with an associated p-value for the likelihood 
of heterogeneity. Results were displayed using forest plots.  
3. RESULTS 
The flowchart for searches is shown in Fig. (1). We 
identified 244 articles in our initial search and a further two 
from scanning reference lists. We removed duplicates leav-
ing 147 titles and abstracts. The main reasons for exclusion 
at this stage were: the risk of the index conditions not being 
the primary focus of the study, review or editorial type 
articles, restriction to children or small subgroups and use of 
biological markers as reported outcome measures. We 
subsequently reviewed 31 full-texts, eight of which met the 
inclusion criteria. Reasons for exclusion are shown in Fig. 
(1). All included studies had a score of “satisfactory” or 
above on the Newcastle-Ottawa score [15], with seven 
studies being rated as “good” or “very good” (see Appendix 
1). The most common areas of potential bias were recall bias 
(use of self-report), reporting bias (use of hospital discharge 
data) and selection bias (male or female only populations).  
3.1. Asthma as a Risk Factor for Type 2 Diabetes 
3.1.1. Study Characteristics 
The characteristics of the four included studies which 
evaluated the risk of incident T2DM in people with asthma 
are displayed in Table 1 [21-24]. These studies included a 
total of 184,387 participants (range 7,176 [23] to 94,511 
[21]) from two countries (USA and Singapore). All four 
were cohort studies and assessed the risk of incident T2DM 
in patients with asthma. Two study populations were com-
prised solely of women, while the other two were mixed 
populations. All excluded patients with T2DM at baseline 
and participants were followed up for 5.7-12.2 years. Cases 
of incident T2DM were detected by self-report in three stud-
ies and by database linkage in one.  
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Fig. (1). Flowchart to show included studies. 
 
Table 1. Studies examining the risk of T2DM in people with asthma. 
Author Study Design Population Method of Case Detection 
Separation of 
T1 & T2DM? 
Comorbidities Consid-
ered 
The result 
(95%CI) 
Authors’ Conclu-
sions 
Rana et al., 
2004 [21] 
Prospective 
cohort 
USA 
Nurses’ Health Study 
2879 asthma cases 
91632 controls 
Age 30-55 
Median follow up 8 years 
Self-reported physician-
diagnosed asthma.  
Biannual questionnaire about 
incident T2DM-diagnosis or 
insulin/oral anti-diabetic 
prescription 
Yes 
T2DM only 
Accounted for BMI, 
smoking, family history 
of diabetes. 
No data on asthma 
severity. Prevalence of 
oral steroid documented. 
RR 1.0  
(0.8-1.2) 
No relationship 
between asthma and 
T2DM risk, but 
relationship was 
seen between COPD 
and incident T2DM 
Song et al., 
2010 [22] 
Prospective 
cohort 
USA 
Women's’ Health Study 
3368 patients with asthma 
32248 controls 
Age >=45 
Median follow up 12.2 years 
Self-report of physician-
diagnosed asthma at baseline 
Annual questionnaire about 
incident T2DM (verified with 
follow up questionnaire) 
Yes  
T2DM only 
Accounted for BMI and 
smoking.  
No data on medications 
or asthma severity. 
RR 1.7 (1.5-1.93) 
After adjusting for 
BMI RR 1.37,  
(1.2-1.57) 
Asthma associated 
with an increased 
risk of incident 
T2DM in women 
Yun et al., 
2012 [23] 
Retrospective 
cohort 
USA 
 
2392 asthmatic patients and 
4784 controls.  
57% male 
44% of patients under 18 at 
end of the study period 
Median follow up 7 years 
asthmatic and 5.8 years non-
asthmatic patients 
A search of large healthcare 
database with records from 
primary and secondary care.  
Note study period 1964-1983 
No Did not account for BMI 
and smoking.  
No data on medications 
or asthma severity.  
HR 2.11 
(1.43-3.13) 
Asthma increased 
the risk of incident 
diabetes 
Mueller et 
al., 2013  
[24] 
Prospective 
cohort 
Singapore 
5115 cases of asthma 
41969 controls 
Age 45-74 
Mean age 46.5 
Median follow up 5.7 years 
Self-reported physician-
diagnosed asthma at baseline 
Incident DM classified if 
developed anytime between 
enrolment and the follow-up 
an interview at the end of the 
study 
Yes 
T2DM only 
Accounted for BMI, 
smoking, passive 
smoking.  
No data on medications 
or asthma severity 
HR 1.31  
(1.00-1.72).  
After adjusting for 
BMI HR 1.25  
(0.95-1.64) 
In the group with 
BMI >27.5  
HR 1.95  
(1.12-3.41) 
Positive association 
between asthma 
T2DM risk, attenu-
ated by adjustment 
for BMI.  
Association reached 
significance in BMI 
>27.5 subgroup 
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3.2. Association Between Asthma and Incident T2DM 
3.2.1. Narrative Synthesis 
Two included studies reported a significantly higher risk 
of T2DM in participants with asthma (RR 1.37, 95% CI 1.2-
1.57 and HR 2.11, 95% CI 1.43-3.14) [22, 23]. Song et al. 
examined a prospective cohort of female health professionals 
followed up over 12.2 years [22]. Participants with pre-
existing asthma had a higher risk of developing T2DM com-
pared with a control group, after adjustment for BMI, smok-
ing and family history of diabetes (RR 1.37, 95% CI 1.2-
1.57). Prior to adjustment for BMI, the RR was 1.70 (1.5-
1.93). Diagnoses of asthma and incident T2DM were ascer-
tained by self-report of a physician diagnosis. A subset of 
those who reported a T2DM diagnosis were then validated 
using physician-led telephone interviews, with a positive 
predictive value of >91%. In a retrospective cohort study by 
Yun et al. [23], 2,392 people with asthma and 4,784 non-
asthmatic controls were compared for their risk of incident 
pro-inflammatory conditions: Inflammatory Bowel Disease 
(IBD), Rheumatoid Arthritis (RA), Coronary Artery Disease 
(CAD) and diabetes (type 1 or type 2). The asthma cohort 
was identified using predetermined diagnostic criteria and 
cases of diabetes were obtained from electronic healthcare 
database codes. The majority of the patients had childhood-
diagnosed asthma (mean age of diagnosis 15 years, median 
age 5 years). Over a median follow-up period of seven years 
for the asthma group and 5.8 years for controls, asthma 
status was associated with an increased risk of incident dia-
betes (HR 2.11, 95% CI 1.43-3.14). Importantly, this was not 
adjusted for BMI, and cases of T1DM and T2DM were not 
distinguished. Forty-four percent of patients were still under 
18 at the end of follow up. 
After adjustment for BMI, two included studies did not 
observe a significant relationship between asthma and 
T2DM (RR 1.0, 95% CI 0.8-1.2 [20] and HR 1.25, 95% CI 
0.95-1.64 [24]). Rana et al. [21] observed no difference in 
T2DM risk between 2879 participants with asthma and 
91632 participants without over an 8 year follow-up period 
(RR 1.0, 95% CI 0.8-1.2). T2DM cases were identified by 
the participant-reported fulfillment of the known interna-
tional diagnostic criteria or the prescription of insulin or anti-
diabetic therapy. BMI was adjusted for. A cohort of patients 
with Chronic Obstructive Pulmonary Disease (COPD) was 
also identified, and an increased incidence of T2DM was 
seen in that group compared to controls RR 1.8 (1.1-2.0). 
Mueller et al. [24] observed a significant association be-
tween self-reported physician-diagnosed asthma and incident 
T2DM over a 5.7 year follow-up period in the Singapore 
Chinese Health Study. After adjustment for BMI, this find-
ing did not reach significance (HR 1.25 95% CI 0.95-1.64). 
The asthma-diabetes association was stronger for adult ver-
sus childhood-onset asthma (HR 1.62 [95% CI 1.03-2.55] 
and HR 1.12 [95% CI 0.65-1.93] respectively), and for 
overweight- versus non-overweight patients (HR 1.69 
[95%CI 1.05-2.73] vs. HR 1.10 [95% CI 0.79-1.53]). 
3.2.2. Meta-analysis 
The four included studies were of sufficiently similar 
study design to allow the calculation of pooled effect size by 
meta-analysis. In the pooled sample there was a significant 
trend towards a greater risk of incident diabetes in those with 
asthma in both the fixed effect model HR 1.34 (95%CI 1.19-
1.53; p<0.001) and random effects model HR 1.37 (95%CI 
1.12-1.69; p=0.001). There were too few studies to reliable 
estimate heterogeneity (Tau²=0.147%; I²=58.8% [95%CI 
0.0-86.3%]) although it appears that there was a reasonable 
agreement between the studies (see Fig. 2).  
We intended to check for asymmetry in the distribution 
of effect sizes using funnel plots, where studies were pooled, 
to assess the possibility of publication bias. However, there 
was an insufficient number of studies to warrant this analysis 
[25].  
3.3. Type 2 Diabetes as a Risk Factor for Asthma 
3.3.1. Study Characteristics 
The characteristics of the four included studies which 
evaluated the risk of incident asthma in people with T2DM 
are displayed in Table 2 [10, 26-28]. The studies included a 
total of 2,750,012 participants (range 34,728 [27] to 
1,811,228 [10]) from three countries (USA, Taiwan and 
Denmark). Two were cross-sectional studies and two were 
retrospective cohorts. Two examined the incidence of asthma 
in patients with T2DM, and two assessed the prevalence. 
The cohort studies excluded patients with asthma at baseline. 
Three studies used data from the large health record data-
bases and one used survey responses from a large twin study. 
Two studies accounted for BMI, one adjusted for ‘obesity’ 
but not specifically BMI, and one did not adjust for weight at 
all.  
Pooled effect estimates were not calculated due to sig-
nificant selection and methodological differences between 
the studies.  
 
Study
Fixed  effect model
Random effects model
Hete roge ne it y: I
2
 = 5 9%,  _
2
 = 0 .02 57 , p  = 0 .0 6
Rana et al. (2004)
Song et al. (2010)
Yun et al.  (2013)
Mueller et al.  (2013)
TE
0.12
0.32
0.75
0.22
seTE
0.1303
0.0974
0.2007
0.1393
0.5 1 2
Hazard R atio
HR
HR
1.34
1.37
1.13
1.38
2.12
1.25
95%-CI
[1.19; 1.53]
[1.12; 1.69]
[0.88; 1.46]
[1.14; 1.67]
[1.43; 3.14]
[0.95; 1.64]
(fixed )
100.0%
--
24.5%
43.8%
10.3%
21.4%
Weigh t
(random)
--
100.0%
26.3%
31.9%
17.0%
24.9%
Weight
Figure 2: Forrest Pl t of Meta-Analysis
 
Fig. (2). Forrest plot of meta-analysis. 
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Table 2. Studies examining the risk of asthma in people with T2DM. 
Author Study Design Population 
Method of Case 
Detection 
Separation of 
T1 & T2DM? 
Comorbidities 
Considered 
Result 
(95%CI) 
Authors’ Conclusions 
Hashemzadeh et 
al., 2009  
[26] 
Cross-sectional 
USA 
Hospital inpatients 
293124 with T2DM 
552624 controls 
97% males.  
Mean age 65 
Control group with HTN 
Hospital discharge data Yes  
T2DM only 
Did not adjust for 
BMI  
 
No data on medica-
tions 
OR 2.99 
(2.92-3.06) 
Prevalence of asthma signifi-
cantly higher in hospitalised 
patients with T2DM than in 
controls 
Ehrlich et al., 
2010  
[10] 
Retrospective 
cohort 
USA 
Health records 
77637 participants with DM 
1733591 controls 53.4% male 
Median age 51 
Follow up 6 years 
Asthma cases identi-
fied by hospital 
discharge  
DM cases detected 
using diabetes registry  
No Adjusted for 
smoking and BMI.  
No data on medica-
tions 
HR 1.08 
(1.03-1.12) 
Individuals with DM were at 
an increased risk of asthma.  
No relationship between 
HbA1c and incidence of 
asthma 
Thomsen et al., 
2011  
[27] 
Cross-sectional 
twin study 
Denmark 
Twin database 
459 with T2DM.  
34293 controls` 
46% of males 
Median age bracket 41-50 
Self-reported asthma 
diagnosis by question-
naire. 
DM cases detected 
using diabetes registry 
Yes 
T2DM only 
Controlled for BMI, 
smoking, and 
COPD.  
No data on medica-
tions 
Men OR 
1.70  
(1.07-2.7) 
Women OR 
1.88 (1.24-
2.85) 
Prevalence of asthma was 
almost doubled in twin with 
T2DM compared with non-
diabetic twin  
Chen et al., 2017 
[28] 
Retrospective 
cohort 
Taiwan 
19428 patients with diabetes 
and 38856 matched controls 
49% of males 
Mean age 62 
Medical claims data No 
Note however 
84.7% of the 
DM patients 
were not on 
insulin 
Accounted for 
obesity (not BMI) 
Data on insulin and 
antidiabetic medica-
tions 
HR 1.30 
(1.24-1.38) 
Risk of incident asthma 
higher in patients with diabe-
tes. 
(Insulin use may increase the 
risk of developing asthma, 
metformin use may reduce the 
risk of developing asthma) 
 
3.1.1.1. Association Between T2DM and Asthma  
3.1.1.1.1. Narrative Synthesis 
All four studies included reported higher rates of asthma 
in participants with diabetes. Two studies reported an in-
creased prevalence of asthma in participants with T2DM 
[26,27], and two reported an increased incidence of asthma 
in participants with diabetes [10, 28]. Of the prevalence stud-
ies, Hashemzadeh et al. [26], used hospital discharge data to 
compare the prevalence of asthma in 293,124 hospital inpa-
tients with T2DM and 552,624 non-matched controls with 
hypertension. Asthma was present in 4.5% of patients with 
T2DM compared with 2.9% of controls. After adjustment for 
comorbidities, T2DM remained independently associated 
with asthma (OR 2.99, 95% CI 1.92-3.06). Notably, the 
study was conducted in a population comprising of 97% 
males. Furthermore, only hospital discharge data were used, 
and BMI was not accounted for. No data were obtained re-
garding the duration of diabetes and asthma diagnoses and 
hence no means of assessing the temporality or direction of 
the relationship. A Danish study of 34,782 twins [27] 
showed that the prevalence of asthma was significantly 
higher in people with T2DM compared to controls in both 
males (13.5% vs. 7.5%) and in females (16.6% vs. 9.6%), 
after adjustment for BMI and smoking. Significant genetic 
correlations were found between asthma and T2DM in all 
subjects (0.20, 95% CI 0.01-0.40), and between asthma and 
BMI in women (0.15, 95% CI 0.07-0.22). 
Both incidence studies did not specifically exclude pa-
tients with T1DM, however the median age of participants in 
these studies was 51 years [10] and 62 years [28], and 84.7% 
of participants in the study by Chen et al. were not pre-
scribed with insulin [28]. Ehrlich et al. conducted a large 
retrospective cohort study of Californian patients using 
health care plan data [10]. The cohort consisted of 77,637 
participants with diabetes (T1DM and T2DM) and 1,733,591 
adult controls, with data on potential confounders available 
for a subset. The incidence of asthma was significantly 
higher in the group with diabetes than in the control group, 
and remained so after adjustment for age, smoking and BMI 
(HR 1.08, 95% CI 1.03-1.12). There was no relationship 
between glycated hemoglobin and the incidence of asthma in 
people with diabetes. Like Hashemzadeh et al. [26], the 
authors used primary hospital discharge diagnoses of 
“asthma” for case detection. 
The most recent study investigating the incidence of 
asthma in patients with diabetes was conducted by Chen et 
al. [28] using medical claims data in Taiwan. A retrospective 
cohort, conducted between 2000 and 2010, demonstrated an 
increased risk of asthma in individuals with diabetes as com-
pared to matched controls (13.5 versus 10.3 per 1000 respec-
tively). Results were adjusted for obesity, but not specifically 
for BMI. In contrast to other studies, data relating to anti-
diabetic medications were collected. Participants with diabe-
tes who received more than three prescriptions for insulin in 
a given year were significantly more likely to develop 
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asthma than participants with diabetes who did not use insu-
lin (OR 2.23, 95% CI 1.52-3.58). Meglitinides were also 
shown to demonstrate this effect. Conversely, the risk of 
asthma decreased 25% in people with diabetes who took 
metformin compared with those who did not.  
4. DISCUSSION 
Our systematic review and meta-analysis find an overall 
greater risk of incident T2DM in individuals with asthma, 
after attempts to control for BMI. We also observed a higher 
prevalence and risk of incident asthma in people with 
T2DM, suggesting that the asthma-T2DM relationship may 
be bidirectional, although this relationship could not be 
quantified by meta-analysis due to study heterogeneity. Con-
sideration is also given to residual confounding factors for 
the observed findings. This is the first systematic review of 
epidemiological studies on the interaction between these two 
conditions.  
4.1. Asthma as a Risk Factor for Incident T2DM: Puta-
tive Mechanisms 
4.1.1. Pro-inflammatory Cytokines 
Chronic inflammation was referred to in all of the studies 
investigating asthma as a risk factor for the development of 
T2DM. Asthma is associated with the upregulation of a myr-
iad of pro-inflammatory cytokines; TNFα, IL-6, IL-8 and 
adhesion molecules, likely through its activation of nuclear 
factor-kB [24]. Elevated levels of these cytokines have been 
shown to be associated with an increased risk of T2DM [28]. 
It has been suggested that chronically elevated levels of these 
cytokines in asthma may lead to the development of insulin 
resistance and eventual T2DM. However, the cytokine re-
sponse in asthma is mainly localized to the airways, and 
hence the mechanism by which isolated airways inflamma-
tion may lead to insulin resistance remains unclear. 
Notably, data discussed in this review from a large 
American cohort of nurses [21] did not demonstrate an in-
creased risk of T2DM in the asthma group but did in COPD 
patients. The authors suggested that this may be due to the 
differences in the cellular infiltrates associated with asthma 
and COPD, with a Th2 helper cell predominance in asthma 
compared with a Th1 predominance in COPD. This proposi-
tion was declined by Song et al., who conducted a similar 
study in American women, [22] stating that this has not been 
supported by other experimental or observational data, and 
proposed that differences in lifestyle variables and length of 
follow-up could explain the differences between their study 
and that of the nursing cohort (21]. There do not appear to be 
any critical differences in baseline characteristics between 
the populations involved in the two studies in question, with 
both accounting for similar confounding variables (BMI and 
smoking), and both separating out COPD patients. Yun et al. 
[23] also referred to pro-inflammatory cytokines in their 
study investigating incident diabetes in asthma. Cases of T1 
and T2DM were not distinguished, and hence more than one 
mechanism may be responsible for their observations.  
4.1.2. Intermittent Hypoxia 
Intermittent hypoxia, has been shown to be associated 
with the phenotype of obese adult asthma [30], has also been 
suggested to worsen glucose control [31]. This fits with two 
studies included in this review [22, 24] in which the asthma-
T2DM link was not significant in those with a normal BMI, 
but was in the overweight or obese groups. Importantly, hy-
poxia in obese asthma may be mediated by Obstructive 
Sleep Apnoea (OSA), and pure asthma in the absence of 
OSA would be highly unlikely to induce hypoxia.  
4.1.3. Confounding Factors 
A key confounding factor which was not accounted for in 
any of the included studies was the prescription of oral ster-
oids. A short course of prednisolone is often prescribed dur-
ing acute exacerbations of asthma, and regular oral predniso-
lone is occasionally prescribed in severe asthma, refractory 
to inhaled treatments. The prevalence of steroid-induced 
diabetes in patients with respiratory illness has been reported 
to be as high as 14.7% [32]. Oral steroids could therefore 
have a significant impact upon the T2DM risk in asthma 
patients. There are mixed data relating to the effect of in-
haled corticosteroids, which are prescribed for the vast ma-
jority of patients with asthma on diabetes incidence, al-
though they may worsen glycaemic control in those with 
established diabetes [33]. Inhaled corticosteroid prescription 
was not assessed in any of the included studies.  
4.2. T2DM as a Risk Factor for Incident Asthma: Puta-
tive Mechanisms 
4.2.1. Microvascular Damage – the “Diabetic Lung” 
In addition to asthma as a risk factor for T2DM, this re-
view also found higher rates of asthma in people with 
T2DM. This adds to emerging evidence which suggests that 
the lung may be a target organ for diabetic microangiopathy. 
Many diabetic complications result from capillary damage, 
yet despite having a very large capillary network, pulmonary 
complications of diabetes are rarely reported. Changes in the 
lung are likely to remain subclinical due to the great mi-
crovascular reserve in the alveolar-capillary network [34].  
Microvascular damage as a result of diabetes has been 
demonstrated by assessment of the diffusion capacity for 
carbon monoxide (DLCO), which is influenced by alveolar-
capillary membrane thickness and pulmonary blood flow. 
The general consensus from numerous studies in patients 
with both T1 and T2DM demonstrate a reduced DLCO in 
comparison with controls, in a manner which correlates with 
the severity of other microvascular complications [34, 35). 
Histopathologically, a thickened alveolar-capillary mem-
brane has been demonstrated in individuals with diabetes 
suggesting that, as in retinopathy and nephropathy, increased 
vessel wall thickness is the pathological hallmark [34).  
4.2.2. Functional Lung Effects 
A meta-analysis of 40 studies evaluating pulmonary 
function in participants with diabetes-free from overt pulmo-
nary disease reported a modest but significant reduction in 
FEV1 and FVC, in a restrictive lung disease pattern [36]. 
These findings are therefore not uniformly consistent with 
the obstructive deficit characteristic of asthma, making it 
difficult to attribute incident asthma wholly to diabetic mi-
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croangiopathy of the lung. Nonetheless, restrictive spirome-
try is seen in patients with asthma who are obese [37], older 
and female [38], and thus asthma induced by the “diabetic 
lung” may manifest in a similar way to this. Poorer control 
of bronchial smooth muscle tone (potentially due to auto-
nomic neuropathy) [34, 39] has been reported, and decre-
ments in lung function have also been seen in patients with 
impaired fasting glucose [40], a subset of “pre-diabetes”. 
Changes seen in “the diabetic lung” are likely to be subclini-
cal in the majority but may become clinically important in 
patients with comorbid lung conditions [34] or pulmonary 
disease risk factors. In these patients, T2DM may lead to the 
unmasking of respiratory symptoms or worsening of control.  
4.2.3. T2DM Treatments 
The study by Chen et al. [28], which found a higher inci-
dence of T2DM in those treated with insulin or meglitinides 
and a lower rate in those taking metformin, raises the inter-
esting possibility that the incidence of asthma may be influ-
enced by T2DM treatments. The lung is known to have insu-
lin receptors, and high levels of insulin binding may promote 
airway smooth muscle contraction and hyper-responsiveness 
[41]. Meglitinides increase the release of insulin from beta 
cells. A higher asthma incidence in patients prescribed 
meglitinides adds further backing to the proposal that 
hyperinsulinemia plays a role in the observed asthma-
diabetes relationship [42]. Moreover, whilst the insulin-
asthma relationship could have been confounded by a high 
number of patients with T1DM being represented in the in-
sulin group, this would not be the case with meglitinides, 
which are solely used for T2DM.  
Metformin has been shown to reduce the risk of incident 
asthma [28]. Metformin is known to be a pharmacological 
adenosine monophosphate-activated protein kinase (AMPK) 
activator [43]. AMPK plays a role in reducing airway 
inflammation and has anti-oxidative and anti-tissue 
remodeling properties [44]. Consequently, metformin may 
have a role in the control of asthma in patients with elements 
of the metabolic syndrome, and this may be a target for fur-
ther research.  
4.2.4. Confounding Factors 
Although all four included studies reported an increased 
risk of asthma in patients with diabetes, two studies did not 
separate cases of T1 and T2DM [10, 28]. We are therefore 
unable to solely attribute our findings to T2DM and have to 
consider the effect T1DM may have on asthma risk. Previous 
work has found a positive association between T1DM and 
asthma onset, suggesting a shared susceptibility to both con-
ditions [45]. A positive relationship between T1DM and in-
cident asthma may be due to the effect of insulin as dis-
cussed above [41, 42].  
Other residual confounders which may have had an im-
pact upon results include smoking, which was not controlled 
for in two studies [26, 28] as it is a known risk factor for 
T2DM [46] and precipitant of obstructive airways disease.  
4.3. Is there a Bidirectional Relationship Between T2DM 
and Asthma? 
A significant trend towards incident diabetes in individu-
als with asthma was demonstrated by meta-analysis in this 
review. All four of the examined studies referred to the 
chronic inflammatory state and cytokine over-expression 
induced by asthma as the potential driving force for the de-
velopment of diabetes 
However, in light of the evidence reviewed, it is likely 
that this is not a unidirectional relationship. A higher preva-
lence and incidence of asthma in people with T2DM was 
also observed. This may be due in part to diabetic complica-
tions in the lung at a microvascular level, however, it is not 
clear how this translates into obstructive lung function and 
airway hyper-responsiveness. These findings lead us towards 
a likely bidirectional relationship. 
4.4. No Independent Relationship? 
Despite the meta-analysis favoring asthma as a risk factor 
for T2DM, two studies did not demonstrate this after control-
ling for BMI [21, 24], and the risk of T2DM was highest in 
obese asthmatics [24]. Obesity plays a significant role in 
each of the arguments discussed. Obesity may increase 
T2DM risk in the same ways that we propose asthma can: 
through a low-grade inflammatory state and the stress of 
intermittent hypoxia. Obesity may increase the risk of 
asthma in similar ways to those we have attributed to T2DM: 
adverse effects on chest mechanics and via increased insulin 
resistance, requiring increased insulin doses and subsequent 
bronchoconstriction. Obesity could therefore, represent more 
than a confounding variable but a key component of a more 
complex metabolic relationship involving three conditions.  
4.5. Limitations of the Available Evidence 
This review used a comprehensive methodology follow-
ing PRISMA [11] and MOOSE [12] guidelines, in which all 
included studies met satisfactory quality requirements [15] 
and represent data from nearly three million participants.  
Only eight studies met the inclusion criteria; four for 
each arm of the bidirectional relationship. The high level of 
heterogeneity between the four T2DMasthma studies pre-
cluded calculation of an overall effect size as two were 
cross-sectional (prevalence of asthma) and two were retro-
spective cohorts (incidence of asthma). Whilst studies were 
of sufficient methodological similarity for pooling in 
asthmaT2DM relationship, we were unable to evaluate 
asymmetry in the distribution of effect sizes using funnel 
plots to assess the possibility of publication bias due to an 
insufficient number of studies. Observational studies are at 
high risk of publication bias, especially those which report 
associations between a number of different conditions (as 
seen in Rana et al. [21] and Yun et al. [23]), and hence rep-
resents an important consideration here. Despite methodo-
logical similarities, the studies included in the meta-analysis 
were from different populations. Two were female-only 
populations and one had a significant proportion of under 
18s, which could influence the generalisability of the results.  
Methods of index condition detection were not uniformly 
robust. None reached the top standards for case detection as 
per the Newcastle-Ottawa scores [15], with many using da-
tabases or self-report. Self-report of respiratory conditions 
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can lead to the misclassification of asthma as COPD [27], 
which could represent a source of bias. Furthermore, three 
studies used hospital record data alone, potentially only ac-
counting for more severe cases of the index conditions. Ad-
ditionally, whilst studies concerning only T1DM were ex-
cluded from the review, those with mixed diabetic popula-
tions were permitted (three of the eight included), reducing 
the ability to attribute the effect seen solely to T2DM and not 
to diabetes in general.  
5. RESEARCH IMPLICATIONS 
The limitations of the currently available evidence high-
light the need for a large well-designed trial to investigate 
the asthma-diabetes relationship further. Clear strategies for 
the identification of index conditions (avoiding reliance upon 
self-report) and control of important confounders such as 
BMI and oral steroid use is required to conclusively deter-
mine if there is an independent association between asthma 
and diabetes.  
6. CLINICAL IMPLICATIONS 
Prevention of T2DM in high-risk individuals through 
weight loss and increased physical activity is well docu-
mented [47]. Smoking cessation, control of hypertension and 
reducing health inequalities are also important factors [48]. 
Prevention of asthma in high-risk individuals is less clear-
cut, as although numerous associations have been made, sub-
stantiation of causality has yet to be determined. Reducing 
obesity (particularly childhood obesity), tobacco exposure 
avoidance and breastfeeding have all been shown to be one’s 
lifetime risk of asthma, and these are the areas prevention 
strategies could focus upon [49].  
The sum of the literature presented herein demonstrates a 
high rate of comorbid asthma and T2DM and suggests plau-
sible contributory mechanisms for this. If T2DM is a risk 
factor for incident asthma, this highlights the importance of 
modulating the common factor, obesity, to reduce this risk. 
Overweight and obese patients with both conditions should 
be made aware that losing weight could improve both their 
asthma and diabetic control, and helping them to do this 
could form a key component of their care. 
Suggestions have also been made as to the influence of 
medications used in diabetes (metformin, meglitinides and 
insulin) on asthma control. Awareness of the potential co-
occurrence of the two conditions could therefore influence 
the optimal prescribing choices. Regarding the bidirectional 
relationship, the potential for diabetes to be a key modulator 
in asthma pathogenesis adds further weight to ongoing work 
regarding the different phenotypes of asthma, which may 
each benefit from different management. 
CONCLUSION 
Our systematic review and meta-analysis find a greater 
risk of T2DM in individuals with asthma, after controlling 
for BMI. We also observed a higher prevalence and inci-
dence risk of asthma in people with T2DM, suggesting that 
asthma and the T2DM relationship may be bidirectional. 
There are a number of potential underlying mechanisms for 
these observations.  
This is the first systematic review of epidemiological 
studies on the interaction between these two conditions. Fur-
ther work is required to investigate this relationship more, 
with clear index case definitions and control of potential 
confounding factors.  
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